Showing 3921-3930 of 8096 results for "".
- TOGETHER-PsA: Weight Loss Plus PsA Control with Ixekizumab and Tirzepatidehttps://practicaldermatology.com/news/together-psa-weight-loss-plus-psa-control-with-ixekizumab-and-tirzepatide/2485259/In the phase 3b TOGETHER-PsA trial, ixekizumab (Taltz, Eli Lilly) used in combination with tirzepatide (Zepbound, Eli Lilly) was more effective than ixekizumab monotherapy in adults with active psoriatic arthritis (PsA) who also have obesity or are overweight with a
- Contact Dermatitis, Unlabeled Ingredients Among Concerns in Self-Tannershttps://practicaldermatology.com/news/contact-dermatitis-unlabeled-ingredients-among-concerns-in-self-tanners/2485034/A recent review in the Journal of Drugs in Dermatology raised some concerns regarding ingredient safety and adverse reactions. Researchers on the study analyzed the top 50 best-selling sunless tanning products on Amazon
- Small Case Series Shows Promise for Topical Roflumilast in HS Treatmenthttps://practicaldermatology.com/news/topical-roflumilast-shows-early-promise-for-mild-hs-in-case-series/2485022/A prospective case series published in JAAD Case Reports suggests that once-daily topical roflumilast 0.3% cream may be a promising off-label treatment for mild hidradenitis suppurativa (HS).
- Vixarelimab Shows Dose-Dependent Efficacy in Prurigo Nodularis Phase 2b Trialhttps://practicaldermatology.com/news/vixarelimab-shows-dose-dependent-efficacy-in-prurigo-nodularis-phase-2b-trial/2484982/Vixarelimab demonstrated dose-dependent improvements in itch severity and skin lesion clearance in patients with moderate to severe prurigo nodularis (PN), according to new results from a phase 2b randomized clinical trial. Res
- Isotretinoin Slows Growth Rate in Teens, But Final Height Unchangedhttps://practicaldermatology.com/news/isotretinoin-slows-growth-rate-in-teens-but-final-height-unchanged/2484962/Adolescents treated with isotretinoin for acne may experience temporary reductions in height velocity, but the medication does not appear to impact final adult height, according to a new retrospective cohort study published in the
- Most Insurers Cover Botulinum Toxin for Axillary Hyperhidrosis: Analysishttps://practicaldermatology.com/news/most-insurers-cover-botulinum-toxin-for-axillary-hyperhidrosis-analysis/2484933/A new cross-sectional study published in the Journal of Drugs in Dermatology finds that while botulinum toxin is broadly covered by private insurers for the treatment of primary axillary hyperhidrosis, access barriers due to
- FDA Takes First Step Toward Expanding Sunscreen Optionshttps://practicaldermatology.com/news/fda-takes-first-step-toward-expanding-sunscreen-options/2484881/The American Academy of Dermatology Association (AADA) released a statement from organization president Susan C. Taylor, MD, FAAD commending the Food and Drug Administration (FDA) for taking its first significant step in more than 20 years toward expanding safe and
- Survey Shows Common Skin Cancer Terms Often Misunderstoodhttps://practicaldermatology.com/news/common-skin-cancer-terms-often-misunderstood-survey-finds/2484880/A research letter looking at how well patients understand commonly used terminology related to skin published in JAMA Dermatology revealed significant gaps that could hinder informed decision-making, according to the study r
- Moisturizer Effective in Acne Patients Using Topical Therapies: Analysishttps://practicaldermatology.com/news/moisturizer-boosts-skin-barrier-in-acne-patients-using-topical-therapies/2484743/New research showed a novel gel-matrix moisturizer improving skin barrier function and overall skin quality in adults with acne undergoing topical treatment. Researchers from Kenvue and Dermatology Consulting Services evaluated
- Study: Tirzepatide Shows Early Efficacy in Hidradenitis Suppurativahttps://practicaldermatology.com/news/study-tirzepatide-shows-early-efficacy-in-hidradenitis-suppurativa/2484716/New research shows dual GLP-1/GIP inhibitor tirzepatide, a dual GLP-1/GIP receptor agonist currently approved for type 2 diabetes and obesity, may offer a novel therapeutic option for patients with moderate-to-severe hidradenitis suppurativa (HS), according to a sm